Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?

Imran K. Tailor; Nawal F. Alshehry; Syed Z. Zaidi; Mohammed A. Marei; Ibraheem H. Motabi; Mansour Alfayez; Syed Y. Altaf

doi:10.1016/j.hemonc.2020.08.002

Citations

392

Views

Abstract not available for this publication.

Cite this Article (APA)

Imran, K. T., Nawal, F. A., Syed, Z. Z., Mohammed, A. M., Ibraheem, H. M., Mansour, A., Syed, Y. A. (2023). Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2020.08.002